
21 Jan WhiteLab Genomics
David Del Bourgo, CEO and Co-founder
Paris, France
(Private)
WhiteLab Genomics is a French-American TechBio company founded in 2019, leveraging Artificial Intelligence to in silico accelerate and mitigate risks in early-stage R&D within the field of genomic medicine. We’re using biological data guided rational approaches to improve these cell and gene therapies, DNA or RNA-based, addressing both viral and non-viral delivery. We are actively engaged in partnerships with renowned academic institutions (INSERM, Vision Institute of Paris, Brain Institute of Paris, Genethon), biotech and pharmaceutical companies (Sanofi, Debiopharm, SIREN Biotechnology), leveraging our ecosytem (YCombinator, Gingko Bioworks, Co.Lab Bayer). Our tools and approaches are aimed to address critical challenges in the biopharma industry through accelerating target discovery, vector (either viral and non-viral) and payload design, and bioproduction. By bringing together the power of computer sciences and biology, we help our partners develop more genomic medicines, faster and make those revolutionary drugs more accessible, affordable, and safer to patients in need.